In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; ...

Galli M, Gragnano F, Berteotti M, et al., on behalf of the Working Group of Thrombosis of the Italian Society of Cardiology. Citation: Antithrombotic Therapy in High Bleeding Risk Part II: Non-Cardiac ...

A small proportion of patients with STEMI treated via primary PCI experienced late ventricular tachycardia (VT) or ventricular fibrillation (VF), occurring one or more days following the procedure, ...

An impressive 470 cardiovascular clinicians from across the U.S., took part in ACC's 2024 Legislative Conference in Washington, DC, from Sept. 29 to Oct. 1, where key issues like establishing ...

Patients can benefit from better healthcare access and outcomes by services that are enabled by artificial intelligence (AI). The current state of technology is evolving to now allow diagnosis of ...

Statins promote coronary plaque stabilization though collagen pathways independently of low-density lipoprotein level reduction among patients living with HIV. Artificial intelligence–driven ...

The newest clinical guideline released by the ACC and American Heart Association (AHA), in collaboration with seven other societies, provides updated recommendations for perioperative cardiovascular ...

You care for a 75-year-old woman with heart failure (HF) with reduced ejection fraction. For the years you have known her, she has enjoyed spending time with her grandchildren, living independently ...

Below-the-knee (BTK) arterial disease represents a significant challenge in peripheral artery disease (PAD) management, particularly in patients with chronic limb-threatening ischemia (CLTI). CLTI ...

In this episode, Drs. Rosy Thachil, Shashank Sinha, Smadar Kort and Eugene Yuriditsky discuss the critical role of echocardiography (Echo) and point-of-care ultrasound (POCUS) in the cardiac intensive ...

In patients with ATTR-CM, vutrisiran, compared with placebo, was associated with a lower risk of cardiovascular events and all-cause death, according to findings from the HELIOS-B trial presented at ...

New to this year's Summit, the Chest Pain Solution Room offered participants of the Chest Pain – MI Registry and Chest Pain Center Accreditation the opportunity to interact with each other in a ...